Precision Medicine Exeter Innovation Platform (PMEI Platform)
Lead Research Organisation:
University of Exeter
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills. The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers’ understanding of each other’s needs and capabilities. This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ‘entrepreneurs in residence’ schemes. Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.
Organisations
- University of Exeter (Lead Research Organisation)
- AstraZeneca (United Kingdom) (Collaboration)
- Hospira (Collaboration)
- M Squared Lasers Ltd (Collaboration)
- Eli Lilly & Company Ltd (Collaboration)
- Indiana University (Collaboration)
- Beckley Foundation (Collaboration)
- Activinsights (Collaboration)
- Renishaw (United Kingdom) (Collaboration)
People |
ORCID iD |
Publications
Castanho I
(2017)
[P1-144]: TRANSCRIPTIONAL AND EPIGENOMIC PROFILING IN THE ENTORHINAL CORTEX IN AMYLOID AND TAU MOUSE MODELS OF ALZHEIMER's DISEASE
in Alzheimer's & Dementia
Castanho I
(2020)
Transcriptional Signatures of Tau and Amyloid Neuropathology.
in Cell reports
Castanho I
(2018)
P3-123: MAPPING GENOMIC CONSEQUENCES OF ALZHEIMER'S DISEASE PATHOLOGY IN AMYLOID AND TAU MOUSE MODELS
in Alzheimer's & Dementia
Curran HV
(2016)
Keep off the grass? Cannabis, cognition and addiction.
in Nature reviews. Neuroscience
Farkas J
(2020)
Combined effects of exposure to engineered silver nanoparticles and the water-soluble fraction of crude oil in the marine copepod Calanus finmarchicus.
in Aquatic toxicology (Amsterdam, Netherlands)
Jackson JS
(2017)
Altered Synapse Stability in the Early Stages of Tauopathy.
in Cell reports
Kennedy NA
(2019)
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
in The lancet. Gastroenterology & hepatology
Palombo F
(2018)
Detection of Aß plaque-associated astrogliosis in Alzheimer's disease brain by spectroscopic imaging and immunohistochemistry.
in The Analyst
Sazonovs A
(2020)
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.
in Gastroenterology
| Description | ARUK small pump priming grant0 to validate epigenetic and transcriptomic regulation in Bin1 |
| Amount | £3,200 (GBP) |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Alzeimhers Society Junior Fellowship: Functional disruption of inhibitory neurones in tauopathy |
| Amount | £197,655 (GBP) |
| Funding ID | 392 |
| Organisation | Alzheimer's Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2015 |
| End | 03/2018 |
| Description | Alzheimer's Research UK Equipment Grant: Purchase of a high speed Ti-Sapphire laser for multiphoton imaging |
| Amount | £90,000 (GBP) |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2016 |
| Description | Alzheimer's Research UK Network cooperation award. PI: Mark Dallas |
| Amount | £99,000 (GBP) |
| Funding ID | ARUK-NCG2016B-1 |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Alzheimer's Research UK: Functional consequences of impairments to gamma frequency network oscillations in mouse models of dementia. PI: Jon Brown |
| Amount | £279,000 (GBP) |
| Funding ID | ARUK-PG2017B-7 |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Alzheimer's Research UK: Improving Neurotransmission through the Brain's Memory Centres: A Pharmacogenetic Approach to Treating Dementia. PI: Mick Craig |
| Amount | £249,000 (GBP) |
| Funding ID | ARUK-IRG2017B-4 |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Alzheimers Research UK equipment grant |
| Amount | £43,000 (GBP) |
| Funding ID | ARUK-EG2016A-5 |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 02/2017 |
| Description | An alternative approach for assessing drug-induced seizures, using non-protected larval zebrafish |
| Amount | £90,000 (GBP) |
| Funding ID | NC/R001421/1 |
| Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2021 |
| Description | Charity funding - Tariq Ahmad |
| Amount | £10,000 (GBP) |
| Organisation | ForCrohns |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2017 |
| Description | Charity funding - Tariq Ahmad |
| Amount | £60,000 (GBP) |
| Organisation | Cure Crohn's Colitis |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2018 |
| Description | Charity funding Tariq Ahmad |
| Amount | £55,000 (GBP) |
| Organisation | Cure Crohn's Colitis |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Developmental Trajectories of Genomic Regulation in Rodent Models of Amyloid and Tau Neuropathology |
| Amount | £395,924 (GBP) |
| Organisation | Alzheimer's Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2019 |
| Description | EPSRC Research Grant. CONTRAST facility: clinical coherent Raman scattering facility |
| Amount | £1,035,354 (GBP) |
| Funding ID | EP/S009957/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 08/2020 |
| Description | Fast and Flexible Imaging of Excitable Tissues |
| Amount | £100,929 (GBP) |
| Funding ID | EP/R021252/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 05/2020 |
| Description | Feasibility study of vibration mode analysis using a 2-strut model |
| Amount | £4,665 (GBP) |
| Organisation | Renishaw PLC |
| Sector | Private |
| Country | United Kingdom |
| Start | 09/2016 |
| Description | Hospira - Pharmaceutical company - educational collaboration |
| Amount | £84,000 (GBP) |
| Organisation | Hospira |
| Sector | Private |
| Country | United States |
| Start | |
| Description | Industry Funding - Tariq Ahmad |
| Amount | £107,000 (GBP) |
| Organisation | Bristol-Myers Squibb |
| Department | Celgene |
| Sector | Private |
| Country | United States |
| Start | 12/2017 |
| End | 06/2019 |
| Description | Industry Funding - Tariq Ahmad |
| Amount | £120,000 (GBP) |
| Organisation | Celltrion Healthcare |
| Sector | Private |
| Country | Korea, Republic of |
| Start | 12/2017 |
| End | 12/2018 |
| Description | Industry Funding - Tariq Ahmad |
| Amount | £120,000 (GBP) |
| Organisation | UCB Pharma |
| Sector | Private |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 03/2019 |
| Description | Industry Funding: Abbvie - staff |
| Amount | £90,000 (GBP) |
| Organisation | AbbVie Inc |
| Sector | Private |
| Country | United States |
| Start | |
| Description | Industry funding |
| Amount | £96,781 (GBP) |
| Organisation | Janssen Pharmaceutica NV |
| Sector | Private |
| Country | Belgium |
| Start | |
| Description | Industry funding |
| Amount | £119,630 (GBP) |
| Organisation | Celltrion Healthcare |
| Sector | Private |
| Country | Korea, Republic of |
| Start | |
| Description | Industry funding: AbbVie |
| Amount | $1,800,000 (USD) |
| Organisation | AbbVie Inc |
| Sector | Private |
| Country | United States |
| Start | |
| Description | Multiuser Equipment Award: A multiphoton imaging facility for in vitro and in vivo studies of CNS function and disease |
| Amount | £644,000 (GBP) |
| Funding ID | 202936/Z/16/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | NAPP grant: Biosimilars |
| Amount | £50,000 (GBP) |
| Organisation | Napp Parmaceuticals Limited |
| Sector | Private |
| Country | United Kingdom |
| Start | 09/2015 |
| Description | Reducing Risk, Improving Outcomes: Development of Personalised Strategies to Reduce the Impact of Immunogenicity to Anti-TNF Therapy |
| Amount | £120,000 (GBP) |
| Funding ID | M2018-1 Ahmad |
| Organisation | Crohn's and Colitis UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 08/2021 |
| Description | Regulatory genomic variation in rodent models of amyloid and tau neuropathology |
| Amount | £434,000 (GBP) |
| Funding ID | ARUK-PG2018B-016 |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 02/2022 |
| Description | Study of the relationship between the remanence and the holding current on Renishaw Brake Coil Housing |
| Amount | £3,000 (GBP) |
| Organisation | Renishaw PLC |
| Sector | Private |
| Country | United Kingdom |
| Start | 07/2016 |
| Description | Tariq Ahmad - CCUK PhD Studentship for Gareth Walker. Project titled "Investigation of genetic factors determine adverse drug reactions in patients with IBD". |
| Amount | £106,298 (GBP) |
| Funding ID | M14-1 |
| Organisation | Crohn's and Colitis UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Travel award for the Portuguese Society for Neuroscience (SPN) Meeting 2017 |
| Amount | € 500 (EUR) |
| Organisation | Portuguese Society for Neuroscience |
| Sector | Learned Society |
| Country | Portugal |
| Start | 05/2017 |
| End | 05/2017 |
| Description | Understanding the mechanisms of anti-TNF treatment failure in patients with Crohn's Disease: a proteomic analysis of the PANTS cohort (Chanchlani) |
| Amount | € 50,000 (EUR) |
| Organisation | European Crohn's and Colitis Organisation (ECCO) |
| Sector | Charity/Non Profit |
| Country | Austria |
| Start | |
| Title | Activity Informatics Service - https://www.activinsights.com/services/activity-informatics/ |
| Description | Activity Informatics Service - https://www.activinsights.com/services/activity-informatics/ |
| Type Of Material | Physiological assessment or outcome measure |
| Year Produced | 2020 |
| Provided To Others? | No |
| Impact | Activity Informatics Service - https://www.activinsights.com/services/activity-informatics/ |
| Title | Dr. Victoria Stiles has developed an improved measure of external training load in relation to models of injury prevention |
| Description | Dr. Stiles has developed the use of accelerometers/applied established accelerometer metrics for measuring physical activity in large populations to a population of runners in order to develop a better/objective measure of external training load that may be more relevant to injury (models of injury prevention). |
| Type Of Material | Physiological assessment or outcome measure |
| Year Produced | 2016 |
| Provided To Others? | No |
| Impact | N/A |
| Title | New genetic test makes treatment for Crohn's and Colitis safer |
| Description | Research [Crohn's and Colitis UK] funded has led to an exciting genetic discovery that will make treatment for Crohn's Disease and Ulcerative Colitis safer. The study, led by Tariq Ahmad at the University of Exeter, has discovered a gene mutation that will identify people who could be at risk of drug side effects. This will help doctors when they decide the best treatment options for their patients. DNA from approximately 500 patients with Crohn's or Colitis with bone marrow suppression and 680 'control' patients were looked at by Tariq and his team to try and discover other genes linked to this adverse drug reaction. In an exciting breakthrough, the researchers found a link between mutations in a gene called NUDT15 and bone marrow suppression. Many people with Crohn's and Colitis are treated with immunosuppressant drugs azathioprine and mercaptopurine (known as thiopurines). However, about 7% of these people develop an adverse reaction to these drugs called 'bone marrow suppression'. This means that the body's immune system is less able to fight infection. In the past, researchers have looked into what might be causing this reaction, and mutations in a gene called TPMT have been identified. If patients carry this faulty TPMT gene, doctors could either choose not to prescribe azathioprine and mercaptopurine or adjust the dose. However, only a quarter of patients who suffer from bone-marrow suppression have abnormalities in TPMT, which suggests other genes may be involved. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2019 |
| Provided To Others? | No |
| Impact | "This study could have a significant impact for people with Crohn's and Colitis, and all it will take is a simple blood test that could prevent them from taking potentially harmful medication. Drug side effects are just as important to consider as initial symptoms, and we are delighted to have funded a study that will mean that at risk patients are not exposed to treatment that could lead to complications". Helen Terry, Director of Research, Crohn's and Colitis UK |
| URL | https://crohnsandcolitis.org.uk/news/new-genetic-test-makes-treatment-for-crohns-and-colitis-safer |
| Title | Triple Marker invivo imaging |
| Description | Simultaneous imaging of amyloid plaques, blood vessels and neural micro structure in mice invivo |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | None as yet |
| Description | Assessing the validity and feasibility of objectively quantifying training characteristics associated with the development of running related injuries |
| Organisation | Activinsights |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Physical activity and injury questionnaire data has been collected on 40 runners every other week for a period of 12 weeks (between January and April 2016). This intensive monitoring has not been done before but we have been able to recruit sufficient participants who have fulfilled the requirements of the project. We are currently in the process of finalising this analysis in preparation for our first publication from the project. The first publication will inform the feasibility aspects of the project and outline the development of methods used to quantify mechanical training load in runners. |
| Collaborator Contribution | Activinsights have provided us with hardware (activity monitors on loan) and staff time, providing the benefit of their expertise in how they have piloted work in this area in other sports and their support in thinking about the best way to enable findings and algorithms from this work to be incorporated into future monitors with on-board processing capability. Discussions with Activinsights Ltd over the course of the project has confirmed that the work undertaken in this area is of interest, both to them but also in the wider sports community. Wearable devices are being used by a lot of sports teams but they are not currently able to extract meaningful measures of workload from their data. As a result of our collaboration, Activinsights has also been able to help us gain access to contacts at the Lawn Tennis Association (LTA) to discuss the possibility of assessing workload relevant to injury in tennis players. |
| Impact | The first publication (pending - due to be written in 2017) will provide information on the feasibility aspects of the project and outline the development of methods used to quantify mechanical training load in runners. As a result of working on this project, Dr V Stiles has developed expertise with management of large datasets and alternative methods to analyse this type of longitudinal data in STATA (data management and stats package). This is necessary for the handling of larger datasets from future follow-up studies. As a result of our collaboration, Activinsights has been able to help us gain access to contacts at the Lawn Tennis Association (LTA) to discuss the possibility of assessing workload relevant to injury in tennis players. We plan to continue working alongside Activinsights Ltd to enable any algorithms we develop to quantify training load as result of this work and future follow-up work to be incorporated into activity monitors that contain on-board processing capabilities. There is a clear pathway for outcomes from this project to be utilised by the company which will enable runners to personally monitor workload relevant to injury and modify their training programmes accordingly. Developing wearable devices to monitor training load will have a positive bearing on understanding and preventing injury. |
| Start Year | 2015 |
| Description | AstraZeneca - Student Masterclass |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Research Development Manager in the University's Innovation, Impact and Business Directorate engaged with the partner and arranged workshops for students to learn about, and directly experience, industry. |
| Collaborator Contribution | To lead the workshops for students and provide senior staff time and facilities as well as covering accommodation costs for the student cohort. |
| Impact | Designed as part of wider strategy to strengthen our existing relationship, a 'student masterclass' was initiated with AstraZeneca to give students first-hand experience of day-to-day life in a big corporation. Five students from our clinical sciences course visited the company's different departments over a consecutive 7 day period, providing them insight into various business and research activities. This allowed UoE to expand the partnership beyond pure research-led collaborations, in a move to incorporate more human resource and training activities, including talent recruitment and student supervision. This masterclass was extremely well received on both sides and consequently has been renewed for a second year. This is planned to take place in Spring 2017 with more students (up to 10) attending. Once again AstraZeneca will contribute towards the travel and accommodation costs as well as provide a considerable in-kind contribution in staff time given that they plan the agenda, involve several departments and manage the whole week at their facility. AstraZeneca hope that the experience will help them attract talent from UoE in the near future and will also help the industry as a whole to highlight skills gaps to the university to ensure such recruits meet those needs. Equally the Medical School sees huge value in this approach and wishes to recreate the mechanism with other partners interested in similar or related medical fields. It is also something IIB may investigate for different business sectors. |
| Start Year | 2015 |
| Description | Changing learning through chronic cannabidiol administration and its application to cigarette smoking |
| Organisation | Beckley Foundation |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The primary objective of the project is to assess whether cannabidiol has an impact on two learning processes that are important mechanisms by which nicotine addiction may be treated: 1) extinction learning: the overwriting of drug memory with a new non-drug association and 2) reconsolidation: the process whereby a memory when reactivated becomes destabilised and vulnerable to destruction, this allows a drug memory potentially to be 'erased' or considerably weakened through pharmacological manipulations |
| Collaborator Contribution | We are now working closely with the Beckley Foundation who have provided £10k toward staff costs and required the compounds needed to deliver the project |
| Impact | We are in the process of putting together a business plan for our cannabis centre as a result of this work. Our staff are now trained phlebotomists and in fMRI procedures. We have a publication in preparation on the use of cannabinoids in medicine. We hope, dependent on the results of this study, to apply to run a CTIMP on this indication of this compound and apply for a marketing authorisation for this purpose. Through this partnership we have been talking with two other organisations : Steep Hill Laboratories in California US, and the Jocknick Foundation in Sweden, about establishing a centre of excellence of cannabis research at University of Exeter. They have discussed providing a substantial sum which would enable us to engage in high quality, early stage clinical and preclinical research, pre-empting the recent changes in legal status of the drug that have taken place in many countries worldwide. |
| Start Year | 2016 |
| Description | Characterizing mechanistically distinct epilepsy and network hyperexcitability phenotypes with brain wide real-time measurements |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Two complimentary approaches to studying real-time circuit dynamics in a vertebrate brain were pursued; in vivo imaging of neural activity (as reported by an intracellular Ca2+ sensor) and multisite electrophysiological recording. The model system employed was the zebrafish brain. The project was driven by taking on a one year full time undergraduate placement (professional training year) to bring together the expertise of Prof Randall in the study of neural circuits and Prof Charles Tyler (Co-I) in the study of zebrafish to generate an experimental platform in which AstraZeneca have expressed an interest in developing. |
| Collaborator Contribution | AstraZeneca neuroscience iMEd were interested in the use of zebrafish to study neuronal activity in intact CNS circuits, in particular for the progression of drugs that interact with signalling at GABAergic synapses. AZ provided us with molecules to test and unpublished data from their own studies. They also helped us to decide the specific forms of network hyperexcitability that might best be studied. |
| Impact | Work has been presented at conferences and UoE have used it as examples in new grant applications geared at expanding these activities. Notably the imaging work was used as pilot work in two successful equipment grant applications to Alzheimer's Research UK (£43k) and Wellcome Trust Multiuser equipment grant (£600k) awarded to Randall (lead PI) and others (including Tyler) in 2016. These now provide additional specialty capabilities that will enhance the neuroscience field at UoE, widening the scope of research, and resources that will draw in future partnerships. Further bids to the MRC are also being considered. The research team have developed multiple new skills in zebrafish brain imaging, in vivo zebrafish electrophysiology, and novel neurophysiological models of epilepsy. The work also helped in an ongoing move to develop silicone probe-based recording methods in their laboratory. As a result they have submitted one manuscript on the fish brain imaging (revisions of which were completed in November 2016) and are soon to submit another on the brain slice recording. UoE has since hosted a visit from senior AstraZeneca scientists to discuss further collaborations. In addition, in a January 2016 they acted as a co-applicant on a BBSRC grant submission that developed from this project. The real-time images of brain activity in zebrafish have been used in undergraduate teaching and will be further disseminated in a new public engagement activity in 2017. Finally, increased employment of zebrafish imaging for frontline neurotoxic studies in the future may also represent a 3Rs-related impact. |
| Start Year | 2016 |
| Description | Development of Light Sheet Microscopy for Biomedical Applications |
| Organisation | M Squared Lasers Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | In collaboration with M Squared Lasers, the PI - J Moger - will construct a prototype light sheet microscope at the University of Exeter's new Living System institute (LSI). Once in place, the collaboration will perform proof-of-concept experiments to demonstrate the capabilities of light sheet microscopy to leading biomedical researchers, and make modifications according to biomedical requirements. |
| Collaborator Contribution | Equipment, Technical support, custom-build components and image processing/control software Light sheet microscopy (LSM) is an emerging imaging technique that provides non-destructive 3D imaging of biomedical samples using a sheet of light that illuminates a single plane of the sample at a time. The method is ideally suited for applications that require rapid imaging of intact biomedical samples such as tissue biopsies and small organisms and has great potential to transform biomedical microscopy. Because tissues are exposed to only a thin plane of light, photobleaching and phototoxicity are significantly lower when compared to conventional wide-field fluorescence and confocal microscopy. LSM produces well-registered serial sections that are suitable for three-dimensional reconstruction of tissue structures. |
| Impact | Currently pending although outputs from this collaboration are anticipated to be generated during 2017 as the LSI becomes more established. |
| Start Year | 2016 |
| Description | Genomic studies in Alzheimer's disease (AD) relevant transgenic models |
| Organisation | Indiana University |
| Department | School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | new collaboration with Andrew J. Saykin (Indiana University School of Medicine) - paper submitted for publication, preprint: https://www.medrxiv.org/content/10.1101/2023.02.27.23286048v1 |
| Collaborator Contribution | new collaboration with Andrew J. Saykin (Indiana University School of Medicine) - paper submitted for publication, preprint: https://www.medrxiv.org/content/10.1101/2023.02.27.23286048v1 |
| Impact | new collaboration with Andrew J. Saykin (Indiana University School of Medicine) - paper submitted for publication, preprint: https://www.medrxiv.org/content/10.1101/2023.02.27.23286048v1 |
| Start Year | 2023 |
| Description | Genomic studies in Alzheimer's disease (AD) relevant transgenic models (PhD student) |
| Organisation | Eli Lilly & Company Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | This award will strengthen our existing research ties with collaborators at Eli Lilly. It is envisaged that the PI and his team will undertake research exchanges with staff at Lilly as we develop our research into the genomics of neurodegenerative diseases and psychiatric phenotypes. |
| Collaborator Contribution | As part of this work Lilly have agreed to provide samples from their amyloid and tau mice. Lilly would breed, genotype, age and collect tissue samples for both mice lines. Based on the current costs of these lines it is estimated that the costs of breeding, genotyping, aging and sample collection/preparation for the initial genomic work with both lines would be in the region of £50,000 (£35,000 for tg4510 and £15,000 for J20). Eli Lilly will also host a PhD student for 3 months at their facilities to carry out follow up work based on the initial analysis in Exeter, this equates to an in-kind contribution of £15,000. |
| Impact | Eli Lilly provided Professor Mill's group with tissue from animal models of AD, which is currently being analysed in our cutting-edge genomics facilities at UEMS. Initial data has been presented at the Wellcome Trust Epigenomics of Common Diseases meeting in November 2016 by Ms. Castanho. A grant application building on the collaborative work is currently under review. P2D investment has successfully developed a strengthened relationship between the research team and Eli Lilly. This collaboration has formed the basis for a successful joint application to the Alzheimer's Society for £395k, with Eli Lilly providing a commitment to match-fund the bid with a £300k in-kind contribution. Following the project, the University of Exeter are also a named partner on an Eli Lilly doctoral training programme and Eli Lilly will also act as an industry partner on a pending MRC Case studentship application made by Professor Mill. |
| Start Year | 2015 |
| Description | Novel skillsets in longitudinal in vivo imaging and their application to the study of the amyloid beta pathway in mouse models of Alzheimer's disease-associated pathology |
| Organisation | Eli Lilly & Company Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Funds from the PtoD fund supported a post doc salary for 6 months working at Lilly's neuroscience research group in Surrey. He received training in the various surgical, experimental and analytical techniques used to perform in vivo multiphoton imaging of the rodent CNS parenchyma. These skills will then be transferred back to Exeter where we are aiming to establish similar methods for multiple investigations in the Biomedical Neuroscience group, the University of Exeter Alzheimer's Society Doctoral training centre and ultimately The Living Systems institute. |
| Collaborator Contribution | Eli Lilly will provide all of the experimental animals used for Dr Tamagnini's experiments. These are predominantly "J20" mice. These animals are genetically modified to model a key aspect of Alzheimer's disease pathology. The pathology is progressive and age-dependent so the mice need to be aged prior to study. To support our Lilly collaborations around electrophysiology we have very recently started to breed a colony of identical mice in Exeter with MRC funds (and founders donated by Lilly)- having these mice in Devon will facilitate transferring learning back to Exeter. In addition Lilly will provide access to their state of the art in vivo 2 photon imaging microscope. An imaging facility of this nature is not available in Exeter- although obtaining funding for one is a key objective. A recently installed multiuser microscope of this nature in the Bristol University imaging facility charges ~£50 an hour to users. Eli Lilly provided around 300 hours of imaging time in for our research visit to Lilly (an in-kind value of £15000). Lilly also contributed through staff time and accomodation costs of the researcher. |
| Impact | Our post doc received excellent training in in vivo imaging which helped him to obtain a new three year fellowship from the Alzheimer's Society which is now funding him at UoE (£197655). All planned data collection has been completed; analysis is extensive and ongoing. Indeed focus was on gathering due to time the award funded and need to access equipment within this time. Data analysis is ongoing but aspects of the work have already been presented at national and international conferences including a major Alzheimer's disease conference and the world's largest Neuroscience meeting. We will write a paper together on the work and will expand the research into new directions working in partnership. In 4Q 2015 we made two applications, one to Alzheimer's Research UK, and Wellcome Trust to enable us to get the hardware to establish these methods in Exeter. We used data from Dr Tamagnini's work at Lilly as supporting data. Both were awarded: £43,000 from Alzheimer's Research UK and £584,000 from Wellcome Trust. Exeter became a partner (along with Kings) on Lilly's successful BBSRC CTP bid, our relationship was cited as part of this award which will fund 12 collaborative PhD students |
| Start Year | 2015 |
| Description | Personalising Anti-TNF therapy in Crohn's Disease - exploring the immunogenicity of Biosimilar Infliximab (RemsimaTM and InflectraTM) |
| Organisation | Hospira |
| Country | United States |
| Sector | Private |
| PI Contribution | Infliximab (IFX) and Adalimumab (ADA) are monoclonal antibody biologic drugs that work against tumor necrosis factor alpha (TNF-a), used to treat advanced Crohn's disease. Typically 10-40% of patients fail to respond to 12 weeks of therapy (primary non-response, PNR), and a further 23-46% of patients mount an immune response to the drug leading to loss of response (LOR). In February 2015 RemsimaTM and InflectraTM, cheaper biosimilars of Infliximab (the latter made by Hospira), became available in the UK. Using the genomic expertise and patient cohorts available at Exeter, these drugs were investigated to understand how UK patients were responding to the drugs and aiming to personalise anti-TNF therapy for Crohn's Disease patients. |
| Collaborator Contribution | Hospira provided a contribution of £147,382, later increased to £231,000 based on recruitment and project milestones. Additional funding based on future publication milestones is pending. |
| Impact | Definitions of treatment response, remission and loss of response have been developed and validated. Recruitment of the desired 1500 patients taking anti-TNF drugs is nearly complete, with 230 patients successfully enrolled who had either switched to or started on Inflectra. This is more biosimilar-treated patients than originally expected; Hospira has agreed to contribute an additional £83,618 as follow-on funding (total partner contribution, £231,000). A genome wide association study (GWAS) of response and antibody formation has been conducted using a discovery cohort of 600 patients. A replication cohort will comprise the other 900 patients Industry partnership: As a consequence of this study a new partnership has also been stuck with NAPP Pharmaceuticals who market the same biosimilar. They were attracted by the study and supported the University with a £50k educational grant. The project group has also gained further funding from AbbVie (US)$1.8M to conduct transcriptomics, HLA typing and epigenetics, and they will also part fund a post-doc with a contribution of £90k over 3 years to assist with the analysis (total cost £141,637, with the balance funded by the University). Further, negotiations are underway with a biotech company, Genentech, who would like to share genomic data around response to anti-TNF drugs. NHS benefit: Involvement by NHS clinicians and IBD patients in research has increased. Greater participation in our studies has helped to formalise treatment algorithms, patient follow-up and drug monitoring (captured on our web based tool). NHS and UoE have together established the first UK biologic drug & antibody level service and now provide this UK-wide, facilitating smarter, cost-effective use of expensive drugs by the NHS. Full economic cost saving to the NHS is underway. Policy: We will submit our first publication in the second quarter of 2017 with the intent that this will be used to inform the NICE diagnostic workgroup who are developing guidelines around Therapeutic Drug Monitoring (TDM) of Anti TNF in Crohn's disease. The data from this study will be used to support a Diagnostic Report commissioned by the NIHR HTA programme on behalf of NICE. Next: We will further investigate Immunogenicity to anti-TNF therapy, the development of which is a major challenge to current therapy. The temporal evolution of antibodies to IFX and ADA, and the clinical impact of ADA formation on disease activity and health care costs, will also be investigated. Since 2017, we have established new industry collaborations with Celgene and UCB Pharma who have provided in-kind contributions of £107,000 and £120,000 respectively, and Celltrion have provided cash contributions of £120,000 for ongoing studies. Charity funding includes £60,000 from Cure Crohn's and £10,000 from ForCrohn's. |
| Start Year | 2015 |
| Description | Secondment for Dr Isabel Gonzalez-Arcelus |
| Organisation | Renishaw PLC |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | This project supported the 6 month secondment of a University of Exeter Research Development Manager to Renishaw, a global company with core skills in measurement, motion control, healthcare, spectroscopy and manufacturing, with an objective to identify potential synergies and areas for collaboration, and to increase traction between the two parties |
| Collaborator Contribution | Part-funded staff costs and provided facilities and resources. To identify how Renishaw's healthcare arm can connect with the Living Systems Institute and of the joint funding/projects that can be generated. |
| Impact | Prior to the exchange the University engagement with Renishaw was very small. Having a single point of contact embedded within the partner's organisation has enabled interaction to develop quickly and lead to considerable early outcomes. Renishaw is interested in formalising the relationship between the parties, to include a provision of rolling funding for research projects, equipment and provision of courses to Renishaw. The new Living Systems Institute was highlighted by Renishaw Diagnostics as an area of potential interest, although specific academics and theme areas for collaboration will be reviewed on an ongoing basis following the launch of the Institute is in November 2016. Potential also exists for undertaking CPD for Renishaw staff; particularly for Renishaw staff to undergo a Laser safety course. A course tailored to Renishaw's needs is being progressed. Degree Apprenticeships: As a direct result of the exchange, Renishaw are now one of our industry employers for the Digital and Technology Solutions degree apprenticeship, which launched in September 2016. They have 3 apprentices, which equates to income of £81k in fees: £27k per apprentice, with 1/3rd contributed by Renishaw and 2/3rd drawn down as match from the Skills Funding Agency (SFA). Renishaw are keen to build on this partnership and recruit further cohorts of apprentices in subsequent years; anticipated numbers are likely to increase to at least 6 apprentices per year in future (equivalent to £160k per cohort). Magnet Sensors: This is an area of general interest for Renishaw and it is hoped to grow into further collaboration. We have established a small contract research agreement (£3,000+VAT) to study the relationship between the remanence and the holding current on Renishaw's Brake Coil Housing. Study of vibration modes of Hexapod: This is a current problem that Renishaw has within the development of one of its platforms. The idea is for Renishaw to gain a better understanding of the vibration modes that affect the Hexapod. A series of meetings has resulted in the establishment of a small contract research agreement (£4,655+VAT) to study the vibration mode analysis using a simplified model as a starting point and assessing the opportunities to create automatic mode analysis. Exploitation of new materials: Renishaw wrote a letter of support for Geoff Nash's EPSRC fellowship. The fellowship seeks to create techniques and technology that will allow the optical characterisation of biological samples, with sub-wavelength spatial resolution, across the infrared to THz regions of the electromagnetic spectrum. Renishaw's in-kind contribution is around £30,500. |
| Start Year | 2015 |
| Title | NICE: Diagnostics Assessment Programme |
| Description | NICE: Diagnostics Assessment Programme: Therapeutic monitoring of TNF alpha inhibitors in Crohn's disease (LISA TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) : 6.19 The Committee considered the research being conducted on tests to measure levels of TNF-alpha inhibitors and antibodies to TNF-alpha inhibitors in Crohn's disease. The Committee heard from a clinical expert that this is a fast-moving area and a lot of research is being done. It also noted that the UK-based PANTS - Personalised Anti-TNF Therapy in Crohn's Disease - study should provide relevant data; but results are not expected until the end of 2016. The Committee concluded that data from this ongoing research are likely to be important when the guidance is considered for updating in the future. Educational research grants from the Pharma industry and the 'Core' charity and MRC |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Impact | Not at that stage yet |
| Title | Light sheet system |
| Description | The light sheet system that was funded by the IAA is now managed by Matt Winter a central imaging facility. This is in itself an impact since the system has moved from the developmental stage to a tool that is routinely used for biomedical research. |
| Type Of Technology | Software |
| Year Produced | 2022 |
| Impact | Development of Light Sheet Microscopy for Biomedical Applications |
| Description | ARUK Conference - Poster presentation describing our transcript sequencing data |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | ARUK Conference (Southampton, March 2022) - Poster presentation describing our transcript sequencing data |
| Year(s) Of Engagement Activity | 2022 |
| Description | BBC Documentary - Is It Time to Legalise Weed? |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Prof. Celia Morgan made contributions on the BBC Documentary "Is It Time to Legalise Weed?", shown in June 2017. ABSTRACT- Rapper and documentary maker Professor Green has a past relationship with cannabis. Before finding success as a musician he sold weed, and between the ages of 16 and 24 he smoked cannabis every day, but things have changed since then. With those days behind him, Professor Green, aka Stephen Manderson, embarks on a uniquely personal film to take an in-depth look at our relationship with Britain's most popular illegal drug and explore the arguments for and against legalisation. Stephen explores today's booming UK cannabis industry, from the realities of life as a dealer, grower and even weed robber, to the consumers with ever-growing options about how and what they buy. With cannabis laws around the world now changing - as US states like California legalise the drug - Stephen meets those hoping to make their future millions out of legalisation here in the UK. He meets politician Nick Clegg to find out what conversations go on in 10 Downing Street, and the police force who are changing the rules. As he comes to reflect on his background and wrestle with his own past, Stephen explores addiction and the links between cannabis use and mental health. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.bbc.co.uk/programmes/p058dgnq |
| Description | BBC Health: Truth or Scare |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Angela Rippon and Kevin Duala return with the series that gets to the bottom of conflicting and confusing health claims. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.bbc.co.uk/programmes/b0b0569q |
| Description | Iso-Seq Social Club Vol 2 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Iso-Seq Social Club Vol 2 (Feb 2022) - Speaker presentation about Iso-Seq mouse data. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Oxford Nanopore Research Update |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Oxford Nanopore Research Update (Cambridge, November 2022) - An overview of our long-read transcriptome sequencing to identify alternative splicing associated with AD pathology. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Panelist at the MORE Symposium, a Multiomics Research Event from Illumina USA 2021 re Genomic studies in Alzheimer's disease (AD) relevant transgenic models Project |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Panelist at the MORE Symposium, a Multiomics Research Event from Illumina USA 2021 re Genomic studies in Alzheimer's disease (AD) relevant transgenic models Project |
| Year(s) Of Engagement Activity | 2021 |
| Description | Plenary session - European Crohn's and Colitis Organisation (ECCO) Conference, Vienna February 2018. Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn's Disease: 12 month data from the PANTS study. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | 17th February 2018, Vienna, Austria - Twelve-month data from the Personalised Anti-TNF therapy in Crohn's disease Study (PANTS) was presented at the 13th Congress of the European Crohn's and Colitis Organisation (ECCO). The results indicate that the safety and clinical effectiveness, safety and immunogenicity of Celltrion Healthcare's CT-P13 (biosimilar infliximab) in patients with Crohn's disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.[1] The real world, UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively. The PANTS study investigates patient, drug and pharmacokinetic factors that predict anti-TNF treatment failure with the aim of developing personalised anti-TNF strategies to improve patient outcomes. This large real-world prospective cohort study provides valuable data on clinical effectiveness as well as biologic samples for genomic studies. PANTS study investigator Dr Tariq Ahmad, Head of the Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group at the University of Exeter, and Consultant Gastroenterologist at the Royal Devon and Exeter Hospital UK said, "This is the largest prospective study looking at mechanisms of anti-TNF treatment failure in patients with inflammatory bowel disease. We strongly believe that this type of research is essential to allow cost effective, treatment strategies for patients with inflammatory bowel disease in order to maximise benefit and minimise harm. The results from the PANTS suggest there are opportunities to optimise the prevention and management of anti-TNF treatment failure." According to the study, immunogenicity is a significant factor in non-remission for both infliximab and adalimumab at week 54 but can be mitigated by the use of immunomodulators, azathioprine, mercaptopurine and methotrexate. The PANTS study has demonstrated that this risk is in part genetically determined by variants in the HLA region suggesting that personalised treatment algorithms may be on the horizon. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Plenary session - European Crohn's and Colitis Organisation (ECCO) Conference, Vienna February 2018. HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn's Disease |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Currently, we are witnessing major scientific advances in every field of IBD, from understanding the causes of these diseases to milestone developments in diagnostic tools and advanced therapies. The theme for the ECCO Congress 2018 is "Science improving patients' lives," devoting special attention to discoveries and innovations that can have an impact on disease management. In the programme for 2018 we will have special sections on early stage disease, paediatric IBD, prediction, novel treatment strategies, diagnosis and management of dysplasia, best perioperative care and other aspects that are essential for returning our patients with IBD to a normal life. Our basic science session will be devoted to considering the evolving concepts of IBD pathogenesis. In the past, the ECCO Congress attracted more than 6,200 delegates from all over the world, becoming the world's reference IBD event for the presentation and dissemination of advances in the field. It has become an indispensable event for every scientist and clinician with a focus on IBD. Preceding the main congress, there is a wide offer of educational courses covering basic and advanced topics for physicians, nurses, clinical and basic investigators, and pharmaceutical research. Besides the core programme, the organisation is fostering meetings of study groups and committees, facilitating dissemination of ongoing research projects supported by the European Commission with ECCO involvement. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.ecco-ibd.eu/discover-the-programme/scientific-programme.html |
| Description | Poster for Alzheimer's Research UK meeting 2022 re Genomic studies in Alzheimer's disease (AD) relevant transgenic models Project |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Poster for Alzheimer's Research UK meeting 2022 re Genomic studies in Alzheimer's disease (AD) relevant transgenic models Project |
| Year(s) Of Engagement Activity | 2021 |
| Description | Presentation to local participants |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Study participants or study members |
| Results and Impact | Dr. Stiles presented some initial findings from this project to local participant groups (runners who assisted in this research). As the project was a feasibility study, their involvement was critical and has shaped our thinking about whether to continue this project and how we might add to it in terms of developing objective metrics of training load in runners that may be relevant to injury (prevention of injury). |
| Year(s) Of Engagement Activity | 2017 |
| Description | Presentations at Epigenomics of Common Diseases Meeting & Presentation at the Epigenomics of Common Diseases conference re Genomic studies in Alzheimer's disease (AD) relevant transgenic models Project |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Presentations at Epigenomics of Common Diseases Meeting. Presentation at the Epigenomics of Common Diseases conference 2021: Wellcome Trust Centre, Cambridge, UK re Genomic studies in Alzheimer's disease (AD) relevant transgenic models Project |
| Year(s) Of Engagement Activity | 2021 |
| Description | Prof. Jonathan Mill. Conference poster: Alzheimer's Association International Conference (AAIC'17) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Work that stemmed from the P2D award was presented (conference poster) by a member of Prof. Jonathan Mill's group at the Alzheimer's Association International Conference (AAIC'17) between July 16-20, 2017. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Prof. Jonathan Mill. Conference poster: Alzheimer's Research UK (ARUK) annual conference 2017 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Work that stemmed from the P2D award was presented (as a conference poster) by a member of Prof. Jonathan Mill's group at The Alzheimer's Research UK Conference 2017, which was held on14-15 March and hosted in Aberdeen.The conference brought together scientists from a range of research backgrounds who all share a common mission to defeat dementia. It was an opportunity for researchers to share their knowledge and form new collaborations. Delegates weremainly UK based scientists in the dementia research field from a range of disciplines including neuroscience, psychiatry, molecular biology, neuropathology and genetics. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Prof. Jonathan Mill. Conference poster: GW4 Early Career Neuroscientist Day 2017 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | Work that stemmed from the P2D award was presented (as a conference poster) by a member of Prof. Jonathan Mill's group at GW4 Early Career Neuroscientist Day, 5 June 2017. Specially designed by and for those in the early stages of their neuroscience career, this popular annual event returns with expert talks, networking opportunities and prizes. This one-day event offered the opportunity for researchers across the GW4 to discuss best practice, share experiences and hear directly from experts in their field. The day included talks and breakout sessions focusing on a wide range of topics from scientific techniques to alternative careers; from cellular neuroscience to public engagement. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://sites.cardiff.ac.uk/gw4-2014-v2/all-events/gw4-early-career-neuroscientist-day-2017/ |
| Description | Prof. Jonathan Mill. Conference poster: The Portuguese Society for Neuroscience 2017 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Work that stemmed from the P2D award was presented (as a conference poster) by a member of Prof. Jonathan Mill's group at The Conference of the Portuguese Society for Neuroscience between 25-26 May, 2017. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Prof. Jonathan Mill. Media interview (Care & Cure, the magazine from the Alzheimer's Society) |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Five University of Exeter researchers cycled an astonishing 350 miles from London to Paris to raise money for Alzheimer's Society. The team comprised Andy Randall, lead of our Exeter Doctoral Training Centre, Society fellow Francesco Tamagnini, geneticists Jonathan Mill and Eilis Hannon, and stem cell researcher Talitha Kerrigan. They had to deal with torrential rain, extreme pain and sheer exhaustion, but made it to the French capital in one piece. They raised an amazing £11,500 as a reward for their efforts. Dr Tamagnini said, 'I have never done anything so hard. I have met new friends and I have consolidated the bond with the rest of the Exeter crew. I realised I love cycling. And I realised, spending four days and suffering with these guys. Now I know that I will probably have to ride for a lot of miles in the path of scientific research, with my colleagues and friends, to finally find a solution and defeat this dragon. And I know we can make it.' Their dedication did not go unnoticed. Dr James Pickett, Head of Research at Alzheimer's Society, said, 'We are delighted that the team from the University of Exeter have succeeded in completing their gruelling challenge. Not only have they already raised a huge amount of money but they are also doing fantastic research to help us understand, treat and ultimately cure dementia.' |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.alzheimers.org.uk/info/20056/our_care_and_cure_research_magazine/1270/care_and_cure_maga... |
| Description | Prof. Jonathan Mill. Participation in Lilly's open day (oral presentation) [18-Sep 2017] |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Participation in Lilly's open day (oral presentation) |
| Year(s) Of Engagement Activity | 2017 |
| Description | Prof. Jonathan Mill. Talk at the Exeter Neuroscience Seminar Series |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | Talk at the Exeter Neuroscience Seminar Series: Causes and Consequences of Dementia [8-Sep 2017] |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.eventbrite.co.uk/e/exeter-neuroscience-seminar-series-causes-and-consequences-of-dementi... |
| Description | Speaker at the virtual event EpigeneticsGenomic- The Full Picture from Illumina International 2021 re studies in Alzheimer's disease (AD) relevant transgenic models project |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Invited speaker at the virtual event Epigenetics - The Full Picture from Illumina International. 2021Castanho I. et al. Genome-wide DNA methylation signatures of tau and amyloid neuropathology. |
| Year(s) Of Engagement Activity | 2021 |